{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:05:40Z","timestamp":1793066740175,"version":"4.5.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Extraintestinal manifestations (EIMs) occur in one-fifth of patients with inflammatory bowel diseases (IBDs) (Crohn\u2019s disease[CD]; ulcerative colitis [UC]). As advanced therapies (ATs) for IBD become more targeted, effectiveness for luminal disease may not be extrapolatable to EIMs. We conducted a systematic review to evaluate the efficacy of ATs on EIMs in IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted searches in PubMed\/Embase (inception March 2025) for studies of any of the 5 FDA approved AT classes (tumor necrosis factor [TNF] antagonists, Janus kinase [JAK] inhibitors, anti-integrins, anti-interleukins [anti-ILs], and S1P receptor modulators) for musculoskeletal (arthritis, arthralgias), dermatologic (erythema nodosum, pyoderma gangrenosum), or ocular EIMs in patients with IBD. The primary outcome was clinical improvement. The pooled improvement rates by EIM type and AT class were calculated using a random effects model to account for anticipated heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 49 studies were included in the final analysis (6 randomized clinical trials [RCTs], 1 pooled analysis of clinical trials, and 42 observational studies). For musculoskeletal EIMs, TNF antagonists achieved response in 61% of patients, with higher response rates for peripheral (73%) than axial (57%) arthritis. JAK inhibitors were similarly effective (65%) while vedolizumab had significantly lower efficacy (42% improvement), particularly for axial arthritis (12%). For dermatologic EIMs, systemically directed ATs had high efficacy (TNF antagonists 89%, anti-IL 91%). There was a paucity of data on ocular EIMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemically directed ATs (TNF-antagonists, JAK inhibitors, anti-ILs) demonstrated strong efficacy for musculoskeletal or cutaneous EIMs; vedolizumab achieved clinical response in lower rates, particularly for axial arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag075","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:59:27Z","timestamp":1775649567000},"page":"2050-2060","source":"Crossref","is-referenced-by-count":2,"title":["Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-7108","authenticated-orcid":false,"given":"Karan","family":"Sachdeva","sequence":"first","affiliation":[{"name":"Department of Medicine, SUNY Upstate Medical University , Syracuse, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Manik","sequence":"additional","affiliation":[{"name":"Boston University Chobanian & Avedisian School of Medicine , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Chhibba","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-1821","authenticated-orcid":false,"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026093014393529900_izag075-B1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B2","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"2026093014393529900_izag075-B3","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026093014393529900_izag075-B5","doi-asserted-by":"publisher","first-page":"jjaf009","DOI":"10.1093\/ecco-jcc\/jjaf009","article-title":"Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials","volume":"19","author":"Chhibba","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ecco-jcc\/jjae002","article-title":"Beyond the gut: a systematic review and meta-analysis of advanced therapies for inflammatory bowel disease-associated extraintestinal manifestations","volume":"18","author":"T\u00edm\u00e1r","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"key":"2026093014393529900_izag075-B8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026093014393529900_izag075-B9","author":"Wells","year":"2000"},{"key":"2026093014393529900_izag075-B10","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026093014393529900_izag075-B11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American gastroenterological association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/apt.18110","article-title":"Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease","volume":"60","author":"Attauabi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014393529900_izag075-B13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn William","year":"2013","journal-title":"N Engl J Med"},{"key":"2026093014393529900_izag075-B14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for Ulcerative Colitis","volume":"369","author":"Feagan Brian","year":"2013","journal-title":"N Engl J Med"},{"key":"2026093014393529900_izag075-B15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014393529900_izag075-B16","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026093014393529900_izag075-B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026093014393529900_izag075-B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014393529900_izag075-B19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2026093014393529900_izag075-B20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2026093014393529900_izag075-B21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous Risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026093014393529900_izag075-B22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B24","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2026093014393529900_izag075-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B26","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/jgh.16612","article-title":"The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"39","author":"Zheng","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026093014393529900_izag075-B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093014393529900_izag075-B28","doi-asserted-by":"publisher","first-page":"i1692","DOI":"10.1093\/ecco-jcc\/jjae190.1068","article-title":"P0894 impact of Mirikizumab on extraintestinal manifestations of Crohn\u2019s disease in the VIVID-1 study","volume":"19","author":"Vavricka","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B29","doi-asserted-by":"publisher","first-page":"i1170","DOI":"10.1093\/ecco-jcc\/jjae190.0761","article-title":"P0587 Effectiveness and safety of Risankizumab in Crohn\u2019s disease patients from a large Italian cohort: preliminary results from the RESOLVE IgIBD study","volume":"19","author":"Scaldaferri","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B30","doi-asserted-by":"publisher","first-page":"i1679","DOI":"10.1093\/ecco-jcc\/jjae190.1059","article-title":"P0885 therapeutic concepts for Pyoderma Gangrenosum as an extraintestinal manifestation in chronic inflammatory bowel diseases","volume":"19","author":"Guse","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B31","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/apt.70073","article-title":"Effectiveness and safety of Upadacitinib induction therapy for 223 patients with Crohn\u2019s disease: a GETAID multicentre cohort study","volume":"61","author":"Richard","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014393529900_izag075-B32","doi-asserted-by":"publisher","first-page":"i1251","DOI":"10.1093\/ecco-jcc\/jjad212.0793","article-title":"P663 efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations\u2013retrospective study","volume":"18","author":"Livne Margolin","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B33","doi-asserted-by":"publisher","first-page":"i1703","DOI":"10.1093\/ecco-jcc\/jjad212.1071","article-title":"P941 Observational study of tofacitinib in ulcerative colitis in Sweden (ODEN) \u2013 Interim analysis of clinical and biomarker data","volume":"18","author":"Nyberg","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026093014393529900_izag075-B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041076","article-title":"Incidence and course of joint inflammation associated with inflammatory bowel disease in patients undergoing treatment with Vedolizumab\/Ustekinumab: the VEDUSTAR study","volume":"13","author":"Gonzalez Diaz","year":"2024","journal-title":"J Clin Med"},{"key":"2026093014393529900_izag075-B35","doi-asserted-by":"publisher","first-page":"20502","DOI":"10.1038\/s41598-024-70241-9","article-title":"Induction and maintenance of mucosal healing in Crohn\u2019s disease with Ustekinumab in clinical practice across all care levels in Germany (MUCUS)","volume":"14","author":"Baumgart","year":"2024","journal-title":"Sci Rep"},{"key":"2026093014393529900_izag075-B36","doi-asserted-by":"publisher","first-page":"17562848241293938","DOI":"10.1177\/17562848241293938","article-title":"Effectiveness and safety outcomes after long-term (54\u2009weeks) vedolizumab therapy for Crohn\u2019s disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II)","volume":"17","author":"Liebert","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"2026093014393529900_izag075-B37","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.14309\/ajg.0000000000003243","article-title":"Persistence, effectiveness, and safety of Upadacitinib in Crohn\u2019s disease and Ulcerative Colitis in real life: results from a Spanish Nationwide Study (Ureal Study)","volume":"120","author":"Garc\u00eda","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026093014393529900_izag075-B38","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s10620-022-07716-0","article-title":"Endo-histologic normalization is achievable with Tofacitinib and is associated with improved clinical outcomes","volume":"68","author":"Cohen","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026093014393529900_izag075-B39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093014393529900_izag075-B40","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s10067-023-06695-5","article-title":"Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases","volume":"42","author":"Dalal","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026093014393529900_izag075-B41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.dld.2022.09.009","article-title":"Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study","volume":"55","author":"Livne-Margolin","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026093014393529900_izag075-B42","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/ibd\/izad075","article-title":"Impact of Vedolizumab on extraintestinal manifestations in inflammatory bowel disease: results from a descriptive, retrospective, real-world study","volume":"29","author":"Kopylov","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014393529900_izag075-B43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.gastha.2021.12.002","article-title":"Joint disease activity in inflammatory bowel disease-associated peripheral spondyloarthritis stratifies therapeutic response","volume":"1","author":"Lai","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"2026093014393529900_izag075-B44","doi-asserted-by":"publisher","first-page":"17562848211072412","DOI":"10.1177\/17562848211072412","article-title":"Effectiveness of ustekinumab in patients with refractory Crohn\u2019s disease: a multicentre real-life study in Italy","volume":"15","author":"Scribano","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"2026093014393529900_izag075-B45","doi-asserted-by":"publisher","first-page":"i036","DOI":"10.1093\/ecco-jcc\/jjab232.032","article-title":"OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): results from the UPA phase 3 programme","volume":"16","author":"Colombel","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B46","doi-asserted-by":"publisher","first-page":"S-701","DOI":"10.1016\/S0016-5085(21)02382-9","article-title":"Su460 effectiveness of Ustekinumab for management of extraintestinal manifestations of Crohn\u2019s disease","volume":"160","author":"Aboubakr","year":"2021","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B47","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026093014393529900_izag075-B48","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ecco-jcc\/jjab081","article-title":"Ustekinumab for Crohn\u2019s disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study","volume":"15","author":"Straatmijer","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B49","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ecco-jcc\/jjab028","article-title":"Effect of Ustekinumab on extraintestinal diseases in refractory Crohn\u2019s disease","volume":"15","author":"Tursi","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B50","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1007\/s10620-019-05982-z","article-title":"Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new Arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center","volume":"65","author":"Reinglas","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2026093014393529900_izag075-B51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cpt.1712","article-title":"Vedolizumab for inflammatory bowel disease: two-year results of the Initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study: ICC registry - Vedolizumab","volume":"107","author":"Biemans","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026093014393529900_izag075-B52","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/ibd\/zaa010.006","article-title":"P100 real-world comparison of Arthralgias with Infliximab vs. Vedolizumab in the treatment of bio-naive inflammatory bowel disease","volume":"26","author":"Ritter","year":"2020","journal-title":"IBD"},{"key":"2026093014393529900_izag075-B53","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/14712598.2020.1830057","article-title":"Effectiveness of Ustekinumab on Crohn\u2019s disease associated spondyloarthropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)","volume":"20","author":"Macaluso","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026093014393529900_izag075-B54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease: results of the ICC registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B55","doi-asserted-by":"publisher","first-page":"S597","DOI":"10.1016\/S0016-5085(17)32137-6","article-title":"Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn\u2019s disease: a Gemini 2 post hoc analysis","volume":"152","author":"Feagan","year":"2017","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B56","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1093\/ecco-jcc\/jjy222.827","article-title":"P703 The real-world long-term effectiveness of vedolizumab in inflammatory bowel diseases: a single-centre observational study","volume":"13","author":"Macaluso","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B57","doi-asserted-by":"publisher","first-page":"S057","DOI":"10.1093\/ecco-jcc\/jjy222.084","article-title":"DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn\u2019s disease: data from the CELEST study","volume":"13","author":"Peyrin-Biroulet","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B58","doi-asserted-by":"publisher","first-page":"S482","DOI":"10.14309\/01.ajg.0000592876.05700.5e","article-title":"835 Can Ustekinemab relieve the symptoms of IBD-associated arthropathy?","volume":"114","author":"Vizuete","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026093014393529900_izag075-B59","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of Ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a national cohort study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B60","doi-asserted-by":"publisher","first-page":"S-844","DOI":"10.1016\/S0016-5085(18)32863-4","article-title":"Mo1899-joint pain in patients with inflammatory bowel disease treated with Vedolizumab: an extra-intestinal manifestation or a side effect of a gut-specific therapy?","volume":"154","author":"Gold","year":"2018","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B61","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1093\/ecco-jcc\/jjx002.062","article-title":"DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID","volume":"11","author":"Tadbiri","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026093014393529900_izag075-B62","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.dld.2018.02.013","article-title":"The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases","volume":"50","author":"Macaluso","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2026093014393529900_izag075-B63","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026093014393529900_izag075-B64","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.3748\/wjg.v23.i39.7139","article-title":"Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study","volume":"23","author":"Luchetti","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026093014393529900_izag075-B65","doi-asserted-by":"publisher","first-page":"S743","DOI":"10.1016\/S0016-5085(17)32581-7","article-title":"Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from inspirada","volume":"152","author":"Travis","year":"2017","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B66","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014393529900_izag075-B67","doi-asserted-by":"publisher","first-page":"S777","DOI":"10.1016\/S0016-5085(16)32634-8","article-title":"Adalimumab treatment reduces extraintestinal manifestations in patients with moderate to severe Crohn\u2019s disease: a pooled analysis","volume":"150","author":"Louis","year":"2016","journal-title":"Gastroenterology"},{"key":"2026093014393529900_izag075-B68","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1016\/S1590-8658(13)60405-3","article-title":"Outcome of arthralgia in a subgroup of inflammatory bowel disease patients with anti tnf-alpha. A single centre study","volume":"45","author":"Spagnuolo","year":"2013","journal-title":"Dig Liver Dis"},{"key":"2026093014393529900_izag075-B69","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2026093014393529900_izag075-B70","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4321\/s1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn\u2019s disease","volume":"104","author":"Barreiro-de-Acosta","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"2026093014393529900_izag075-B71","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2026093014393529900_izag075-B72","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease","volume":"25","author":"Kaufman","year":"2005","journal-title":"Rheumatol Int"},{"key":"2026093014393529900_izag075-B73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn\u2019s disease","volume":"34","author":"Rispo","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"2026093014393529900_izag075-B74","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2026093014393529900_izag075-B75","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"2026093014393529900_izag075-B76","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn\u2019s disease","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/2050\/68262802\/izag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/2050\/68262802\/izag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:39:44Z","timestamp":1790793584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/10\/2050\/8675293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":76,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag075","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,11]]}}}